Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 5/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31287360 | 1.00 | GPR35 (0.38) | GPR35TSHRKDM4EPKMUSP2 | |
| SCHEMBL2390290 | 0.81 | ALOX15 (0.43) | GPR35KDM4EUSP2ALDH1A1AR | |
| SCHEMBL31500472 | 0.79 | KDM4E (0.41) | GPR35KDM4EUSP2ALDH1A1AR | |
| SCHEMBL31260588 | 0.79 | SRC (0.37) | GPR35KDM4EUSP2ALDH1A1HSD17B10 | |
| SCHEMBL504735 | 0.79 | GPR35 (0.37) | GPR35KDM4EUSP2ALDH1A1AR | |
| SCHEMBL31267048 | 0.79 | GPR35 (0.37) | GPR35KDM4EUSP2ALDH1A1AR | |
| SCHEMBL26927280 | 0.79 | KDM4E (0.41) | GPR35KDM4EUSP2ALDH1A1AR | |
| SCHEMBL363341 | 0.79 | KDM4E (0.45) | KDM4EPKMUSP2ALDH1A1HSD17B10 | |
| SCHEMBL28975511 | 0.77 | TSHR (0.38) | GPR35TSHRKDM4EUSP2ALDH1A1 | |
| SCHEMBL25514816 | 0.77 | KDM4E (0.50) | TSHRKDM4EUSP2ALDH1A1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319426-A1 | Substituted Isoindoles | ASTRAZENECA AB (SE) | 2011-12-29 | — | — | US | disclosed |
| US-8030500-B2 | Substituted isoindoles for the treatment and/or prevention of Aβ- related pathologies | ASTRAZENECA AB (SE) | 2011-10-04 | — | — | US | disclosed |
| EP-2367814-A1 | NEW COMPOUNDS 578 | AstraZeneca AB (SE) | 2011-09-28 | — | — | EP | disclosed |
| US-20100125082-A1 | NEW COMPOUNDS 578 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
| WO-2010056196-A1 | NEW COMPOUNDS 578 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125082-A1 | NEW COMPOUNDS 578 | PSEN1, PSEN2, BACE1 | GPR35 1444/4885TSHR 4613/4885KDM4E 4149/4885 |
| US-20110319426-A1 | Substituted Isoindoles | PSEN2, PSEN1, SNCA | GPR35 974/4885TSHR 4745/4885KDM4E 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.